FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer

The FDA has approved the combination of talazoparib and enzalutamide for patients with metastatic prostate cancer bearing HRR gene mutations, expanding its prior use from castration-resistant to androgen pathway modulation-naïve or -sensitive cases. The approval was based on the phase 3 TALAPRO-3 trial showing significant improvement in progression-free survival and promising trends in overall survival.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 4 sources have reported it.